Involvement of Cot activity in the proliferation of ALCL lymphoma cells

Biochemical and Biophysical Research Communications

Volumn 411, Issue 4, 2011, Pages 655-660

  Fernández, Margarita ^a   Manso, Rebeca ^a   Bernáldez, Flavia ^a   López, Pilar ^a   Martín Duce, Antonio ^a   Alemany, Susana ^a  

^a AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

Author keywords

Cot tpl2; Erk1 2; Lymphoma; P70 S6K; Proliferation; ShRNA

Indexed keywords

COT PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; ONCOPROTEIN; RAF PROTEIN; S6 KINASE; TRANSCRIPTION FACTOR JUNB; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE PROGRESSION; CELL DIVISION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; INHIBITION KINETICS; LARGE CELL LYMPHOMA; LEUKEMIA CELL LINE; LYMPHOMA CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RNA INTERFERENCE; WESTERN BLOTTING;

EID: 80051553809     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.06.157     Document Type: Article

References (33)

1. Falini B., Pileri S., Pizzolo G., Durkop H., Flenghi L., Stirpe F., Martelli M., Stein H. CD30 Ki-1 molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 1995, 85:1-14.
2. Durkop H., Latza U., Hummel M., Eitelbach F., Seed B., Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 1992, 68:421-427.
3. Al-Shamkhani A. The role of CD30 in the pathogenesis of haematopoietic malignancies. Curr. Opin. Pharmacol. 2004, 4:355-359.
4. Horie R., Watanabe T., Morishita Y., Ito K., Ishida T., Kanegae Y., Saito I., Higashihara M., Mori S., Kadin M. Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-Reed-Sternberg cells. Oncogene 2002, 21:2493-2503.
5. Watanabe M., Sasaki M., Itoh K., Higashihara M., Umezawa K., Kadin M., Abraham L., Watanabe T., Horie R. JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and reed-sternberg cells of Hodgkin lymphoma. Cancer Res. 2005, 65:7628-7634.
6. Zheng B., Fiumara P., Li Y., Georgakis G., Snell V., Younes M., Vauthey J., Carbone A., Younes A. MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood 2003, 102:1019-1027.
7. Staber P., Vesely P., Haq N., Ott R., Funato K., Bambach I., Fuchs C., Schauer S., Linkesch W., Hrzenjak A., Dirks W., Sexl V., Bergler H., Kadin M., Sternberg D., Kenner L., Hoefler G. The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling. Blood 2007, 110:3374-3383.
8. Banerjee A., Gugasyan R., McMahon M., Gerondakis S. Diverse Toll-like receptors utilize Tpl2 to activate extracellular signal-regulated kinase ERK in hemopoietic cells. Proc. Natl. Acad. Sci. USA 2006, 103:3274-3279.
9. Rodriguez C., Pozo M., Nieto E., Fernandez M., Alemany S. TRAF6 and Src kinase activity regulates Cot activation by IL-1. Cell. Signal. 2006, 18:1376-1385.
10. Soria-Castro I., Krzyzanowska A., Pelaez M.L., Regadera J., Ferrer G., Montoliu L., Rodriguez-Ramos R., Fernandez M., Alemany S. Cot/tpl2 (MAP3K8) mediates myeloperoxidase activity and hypernociception following peripheral inflammation. J. Biol. Chem. 2010, 285:33805-33815.
11. Gantke T., Sriskantharajah S., Ley S. Regulation and function of TPL-2, an IkappaB kinase-regulated MAP kinase kinase kinase. Cell Res. 2011, 21:131-145.
12. Miyoshi J., Higashi T., Mukai H., Ohuchi T., Kakunaga T. Structure and transforming potential of the human Cot oncogene encoding a putative protein kinase. Mol. Cell. Biol. 1991, 11:4088-4096.
13. Gandara M., Lopez P., Hernando R., Castano J., Alemany S. The COOH-terminal domain of wild-type Cot regulates its stability and kinase specific activity. Mol. Cell. Biol. 2003, 23:7377-7390.
14. Clark A., Reynolds S.A., Wiest M.J. Mutational activation of the MAP3K8 protooncogene in lung cancer. Genes, Chromosomes and Cancer 2004, 41:99-108.
15. Shirali S., Hamoudi R.A., Bench A., Scott M., Ley S.C., Du M.Q. TPL-2 MEK kinase is not targeted by mutation in diffuse large B cell lymphoma and myeloid leukemia. Leuk. Res. 2007, 31:1604-1607.
16. Vougioukalaki M., Kanellis D.C., Gkouskou K., Eliopoulos A.G. Tpl2 kinase signal transduction in inflammation and cancer. Cancer Lett. 2011, 304:80-89.
17. Johannessen C., Boehm J., Kim S., Thomas S., Wardwell L., Johnson L., Emery C., Stransky N., Cogdill A., Barretina J., Caponigro G., Hieronymus H., Murray R., Salehi-Ashtiani K., Hill D., Vidal M., Zhao J., Yang X., Alkan O., Kim S., Harris J., Wilson C., Myer V., Finan P., Root D., Roberts T., Golub T., Flaherty K., Dummer R., Weber B., Sellers W., Schlegel R., Wargo J., Hahn W., Garraway L.A. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010, 468:968-972.
18. Mir S., Richter B., Duckett C.S. Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood 2000, 96:4307-4312.
19. Wright C., Rumble J., Duckett C. CD30 activates both the canonical and alternative NF-kappaB pathways in anaplastic large cell lymphoma cells. J. Biol. Chem. 2007, 282:10252-10262.
20. Rodriguez C., Pozo M., Nieto E., Fernandez M., Alemany S. TRAF6 and Src kinase activity regulates Cot activation by IL-1. Cell Signal 2006, 18:1376-1385.
21. Lin Z., Lim S., Viani M., Sapp M., Lim M. Down-regulation of telomerase activity in malignant lymphomas by radiation and chemotherapeutic agents. Am. J. Pathol. 2001, 159:711-719.
22. Chen J.C., Chang M.L., Muench M.O. A kinetic study of the murine mixed lymphocyte reaction by 5,6-carboxyfluorescein diacetate succinimidyl ester labeling. J. Immunol. Methods 2003, 279:123-133.
23. Fresno Vara J., Caceres M., Silva A., Martin-Perez J. Src family kinases are required for prolactin induction of cell proliferation. Mol. Biol. Cell 2001, 12:2171-2183.
24. Punzon I., Criado L., Serrano A., Serrano F., Bernad A. Highly efficient lentiviral-mediated human cytokine transgenesis on the NOD/scid background. Blood 2004, 103:580-582.
25. Marzec M., Kasprzycka M., Liu X., Raghunath P.N., Wlodarski P., Wasik M.A. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf. Oncogene 2007, 26:813-821.
26. Velasco-Sampayo A., Alemany S. p27kip protein levels and E2F activity are targets of Cot kinase during G1 phase progression in T cells. J. Immunol. 2001, 166:6084-6090.
27. Schmelzle T., Hall M. TOR a central controller of cell growth. Cell 2000, 103:253-262.
28. Vega F., Medeiros L., Leventaki V., Atwell C., Cho-Vega J., Tian L., Claret F., Rassidakis G.Z. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res. 2006, 66:6589-6597.
29. Marzec M., Kasprzycka M., Liu X., El-Salem M., Halasa K., Raghunath P.N., Bucki R., Wlodarski P., Wasik M.A. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway. Oncogene 2007, 26:5606-5614.
30. Ballif B.A., Roux P.P., Gerber S.A., MacKeigan J.P., Blenis J., Gygi S.P. Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6Kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors. Proc. Natl. Acad. Sci. USA 2005, 102:667-672.
31. Lopez-Pelaez M., Soria-Castro I., Bosca L., Fernandez M., Alemany S. Cot/tpl2 activity is required for TLR-induced activation of the Akt p70 S6k pathway in macrophages: Implications for NO synthase 2 expression. Eur. J. Immunol. 2011, 41:1733-1741.
32. Cohen P. Targeting protein kinases for the development of anti-inflammatory drugs. Curr. Opin. Cell Biol. 2009, 21:317-324.
33. Gaestel M., Kotlyarov A., Kracht M. Targeting innate immunity protein kinase signalling in inflammation. Nat. Rev. Drug Discovery 2009, 8:480-499.